Moreover, the 36-month beta value for DYN is 1.13. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 84.07M and currently, short sellers hold a 13.88% of that float. On March 19, 2025, DYN’s average trading volume was 1.97M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has gone rise by 2.19 in comparison to its previous close of 12.31, however, the company has experienced a 4.57% increase in its stock price over the last five trading days. globenewswire.com reported 2025-03-16 that – Continued favorable safety profile for DYNE-251 – – DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 – – Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 – WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose).
DYN’s Market Performance
Dyne Therapeutics Inc (DYN) has experienced a 4.57% rise in stock performance for the past week, with a -9.56% drop in the past month, and a -50.88% drop in the past quarter. The volatility ratio for the week is 6.05%, and the volatility levels for the past 30 days are at 6.41% for DYN. The simple moving average for the past 20 days is -1.44% for DYN’s stock, with a -57.24% simple moving average for the past 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with BMO Capital Markets repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see DYN reach a price target of $50. The rating they have provided for DYN stocks is “Sector Outperform” according to the report published on March 07th, 2025.
Robert W. Baird gave a rating of “Outperform” to DYN, setting the target price at $46 in the report published on December 13th of the previous year.
DYN Trading at -13.52% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.49% of loss for the given period.
Volatility was left at 6.41%, however, over the last 30 days, the volatility rate increased by 6.05%, as shares sank -8.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.59% lower at present.
During the last 5 trading sessions, DYN rose by +4.57%, which changed the moving average for the period of 200-days by -59.52% in comparison to the 20-day moving average, which settled at $12.76. In addition, Dyne Therapeutics Inc saw -46.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Friedl-Naderer Johanna, who sale 143 shares at the price of $12.12 back on Mar 13 ’25. After this action, Friedl-Naderer Johanna now owns 96,057 shares of Dyne Therapeutics Inc, valued at $1,733 using the latest closing price.
Scalzo Richard William, the SVP, Head of Finance & Admin. of Dyne Therapeutics Inc, sale 1,343 shares at $11.38 during a trade that took place back on Mar 11 ’25, which means that Scalzo Richard William is holding 122,330 shares at $15,283 based on the most recent closing price.
Stock Fundamentals for DYN
The total capital return value is set at -0.53. Equity return is now at value -88.03, with -74.14 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -12.19.
Currently, EBITDA for the company is -343.89 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.60.
Conclusion
To wrap up, the performance of Dyne Therapeutics Inc (DYN) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
